Please Wait.....
Report
Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Process (Manual iPSC Production Process, Automated iPSC Production Process), By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services), By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others), By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics), By Region and Competition, 2020-2030F
Market Report I 2025-05-23 I 180 Pages I TechSci Research
Market Overview
The Global Induced Pluripotent Stem Cells (iPSCs) Production Market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.45 billion by 2030, growing at a CAGR of 10.44% during the forecast period. iPSCs have emerged as a transformative innovation in regenerative medicine due to their ability to self-renew and differentiate into multiple cell types. Derived by reprogramming adult cells like those from skin or blood, iPSCs exhibit properties similar to embryonic stem cells while addressing ethical and immunological concerns associated with traditional sources. Their versatility positions them as vital tools for regenerative therapies, drug screening, and disease modeling. With advancements in iPSC technology, the market is expanding rapidly, driven by growing applications across neurology, cardiology, and metabolic disorders. The shift towards personalized medicine and the ethical benefits of using adult-derived cells further bolster demand, establishing iPSCs as a cornerstone in next-generation biomedical research and therapeutic development.
Key Market Drivers
Expanding Therapeutic Applications
The potential of iPSCs in clinical therapy is continuously growing as they are applied to an expanding spectrum of diseases. Their ability to differentiate into various specialized cell types makes them highly promising for treating complex conditions such as Parkinson's disease, Alzheimer's, cardiovascular disorders, and diabetes. iPSCs derived from adult cells can be engineered into dopaminergic neurons, offering targeted treatment pathways and facilitating drug development for neurodegenerative conditions. Similarly, their application in cardiac regeneration is gaining traction, with researchers using iPSC-derived cardiac cells to model heart diseases and explore regenerative options post-injury. The increasing adoption of iPSCs in these therapeutic areas not only enhances treatment potential but also broadens the market for their production, as healthcare systems and patients alike seek advanced, tailored solutions.
Key Market Challenges
Cost of Production
A major limitation hindering the widespread adoption of iPSC technologies is the high cost associated with their generation and maintenance. The reprogramming of adult cells into iPSCs involves resource-intensive processes that require high-end laboratory infrastructure, advanced equipment, and skilled personnel. Furthermore, the culture media and reagents used in iPSC production are costly and must comply with strict quality standards to ensure consistency and safety. These operational expenses create significant financial barriers for both academic and commercial entities attempting to scale production for therapeutic use. Consequently, the cost of iPSC-based therapies remains high, limiting accessibility for broader patient groups and posing challenges for market scalability.
Key Market Trends
Growing Applications in Disease Modeling and Drug Development
The increasing use of iPSCs in disease modeling and pharmaceutical research is a key trend driving market growth. iPSCs can be generated from individuals with specific genetic profiles, enabling the creation of personalized disease models. These models provide valuable platforms for understanding disease mechanisms and testing drug responses in conditions such as genetic disorders, neurodegenerative diseases, and cardiovascular anomalies. Pharmaceutical companies are leveraging iPSC technology to enhance drug discovery pipelines, enabling more accurate candidate screening and reducing development timelines and costs. The rising emphasis on precision medicine further amplifies the need for iPSC-derived models, reinforcing their significance in both academic research and commercial drug development.
Key Market Players
- Lonza Group
- Axol Biosciences Ltd.
- Evotec SE
- Hitachi Ltd.
- Reprocells Inc.
- Fate Therapeutics.
- Thermo Fisher Scientific, Inc.
- Merck KgaA
- Stemcellsfactory III
- Applied Stemcells Inc.
Report Scope:
In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Induced Pluripotent Stem Cells Production Market, By Process:
o Manual iPSC Production Process
o Automated iPSC Production Process
- Induced Pluripotent Stem Cells Production Market, By Product:
o Instruments/ Devices
o Automated Platforms
o Consumables & Kits
o Services
- Induced Pluripotent Stem Cells Production Market, By End-user:
o Research & Academic Institutes
o Biotechnology & Pharmaceutical Companies
o Hospitals & Clinics
- Induced Pluripotent Stem Cells Production Market, By Application:
o Drug Development and Discovery
o Regenerative Medicine
o Toxicology Studies
o Others
- Induced Pluripotent Stem Cells Production Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.
Available Customizations:
Global Induced Pluripotent Stem Cells Production market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Induced Pluripotent Stem Cells Production Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Process (Manual iPSC Production Process, Automated iPSC Production Process)
5.2.2. By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services)
5.2.3. By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others)
5.2.4. By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics)
5.2.5. By Company (2024)
5.2.6. By Region
5.3. Market Map
6. North America Induced Pluripotent Stem Cells Production Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Process
6.2.2. By Product
6.2.3. By End-user
6.2.4. By Application
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Induced Pluripotent Stem Cells Production Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Process
6.3.1.2.2. By Product
6.3.1.2.3. By End-user
6.3.1.2.4. By Application
6.3.2. Mexico Induced Pluripotent Stem Cells Production Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Process
6.3.2.2.2. By Product
6.3.2.2.3. By End-user
6.3.2.2.4. By Application
6.3.3. Canada Induced Pluripotent Stem Cells Production Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Process
6.3.3.2.2. By Product
6.3.3.2.3. By End-user
6.3.3.2.4. By Application
7. Europe Induced Pluripotent Stem Cells Production Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Process
7.2.2. By Product
7.2.3. By End-user
7.2.4. By Application
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Induced Pluripotent Stem Cells Production Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Process
7.3.1.2.2. By Product
7.3.1.2.3. By End-user
7.3.1.2.4. By Application
7.3.2. Germany Induced Pluripotent Stem Cells Production Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Process
7.3.2.2.2. By Product
7.3.2.2.3. By End-user
7.3.2.2.4. By Application
7.3.3. United Kingdom Induced Pluripotent Stem Cells Production Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Process
7.3.3.2.2. By Product
7.3.3.2.3. By End-user
7.3.3.2.4. By Application
7.3.4. Italy Induced Pluripotent Stem Cells Production Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Process
7.3.4.2.2. By Product
7.3.4.2.3. By End-user
7.3.4.2.4. By Application
7.3.5. Spain Induced Pluripotent Stem Cells Production Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Process
7.3.5.2.2. By Product
7.3.5.2.3. By End-user
7.3.5.2.4. By Application
8. Asia-Pacific Induced Pluripotent Stem Cells Production Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Process
8.2.2. By Product
8.2.3. By End-user
8.2.4. By Application
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Induced Pluripotent Stem Cells Production Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Process
8.3.1.2.2. By Product
8.3.1.2.3. By End-user
8.3.1.2.4. By Application
8.3.2. India Induced Pluripotent Stem Cells Production Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Process
8.3.2.2.2. By Product
8.3.2.2.3. By End-user
8.3.2.2.4. By Application
8.3.3. South Korea Induced Pluripotent Stem Cells Production Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Process
8.3.3.2.2. By Product
8.3.3.2.3. By End-user
8.3.3.2.4. By Application
8.3.4. Japan Induced Pluripotent Stem Cells Production Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Process
8.3.4.2.2. By Product
8.3.4.2.3. By End-user
8.3.4.2.4. By Application
8.3.5. Australia Induced Pluripotent Stem Cells Production Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Process
8.3.5.2.2. By Product
8.3.5.2.3. By End-user
8.3.5.2.4. By Application
9. South America Induced Pluripotent Stem Cells Production Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Process
9.2.2. By Product
9.2.3. By End-user
9.2.4. By Application
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Induced Pluripotent Stem Cells Production Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Process
9.3.1.2.2. By Product
9.3.1.2.3. By End-user
9.3.1.2.4. By Application
9.3.2. Argentina Induced Pluripotent Stem Cells Production Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Process
9.3.2.2.2. By Product
9.3.2.2.3. By End-user
9.3.2.2.4. By Application
9.3.3. Colombia Induced Pluripotent Stem Cells Production Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Process
9.3.3.2.2. By Product
9.3.3.2.3. By End-user
9.3.3.2.4. By Application
10. Middle East and Africa Induced Pluripotent Stem Cells Production Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Process
10.2.2. By Product
10.2.3. By End-user
10.2.4. By Application
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Induced Pluripotent Stem Cells Production Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Process
10.3.1.2.2. By Product
10.3.1.2.3. By End-user
10.3.1.2.4. By Application
10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Production Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Process
10.3.2.2.2. By Product
10.3.2.2.3. By End-user
10.3.2.2.4. By Application
10.3.3. UAE Induced Pluripotent Stem Cells Production Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Process
10.3.3.2.2. By Product
10.3.3.2.3. By End-user
10.3.3.2.4. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Lonza Group
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Axol Biosciences Ltd.
15.3. Evotec SE
15.4. Hitachi Ltd.
15.5. Reprocells Inc.
15.6. Fate Therapeutics.
15.7. Thermo Fisher Scientific, Inc.
15.8. Merck KgaA
15.9. Stemcellsfactory III
15.10. Applied Stemcells Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security